# EDGAR Filing Document

**Accession Number:** 0002035832
**File Stem:** 9999999995-26-000113
**Filing Date:** 2026-1
**Character Count:** 1313
**Document Hash:** d4894b7fb3aeaad01209753dce38a2dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-26-000113.hdr.sgml**: 20260109

**ACCESSION NUMBER**: 9999999995-26-000113

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260109

**EFFECTIVENESS DATE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aktis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0002035832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852584233
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292283
- **FILM NUMBER:** 26521233

**BUSINESS ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 978-237-4380

**MAIL ADDRESS:**
- **STREET 1:** 17 DRYDOCK AVENUE
- **STREET 2:** SUITE #17-401
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** January 8, 2026

**Time:** 16:00:00

**Form Type:** S-1

---

**CIK:** 0002035832

**Company Name:** Aktis Oncology, Inc.

**File Number:** 333-292283